Pharmacovigilance: A Practical Approach
Editat de Thao Doan, Fabio Lievano, Linda Scarazzini, Charles Schubert, Barbara Hendricksonen Limba Engleză Paperback – 24 mar 2025
Preț: 473.66 lei
Preț vechi: 629.76 lei
-25% Nou
Puncte Express: 710
Preț estimativ în valută:
90.64€ • 95.07$ • 75.45£
90.64€ • 95.07$ • 75.45£
Carte nepublicată încă
Doresc să fiu notificat când acest titlu va fi disponibil:
Se trimite...
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780443118814
ISBN-10: 0443118817
Dimensiuni: 191 x 235 mm
Greutate: 0.45 kg
Ediția:2nd edition
Editura: Elsevier
ISBN-10: 0443118817
Dimensiuni: 191 x 235 mm
Greutate: 0.45 kg
Ediția:2nd edition
Editura: Elsevier
Cuprins
SECTION 1 THE REGULATORY ENVIRONMENT AND THE PHARMACOVIGILANCE QUALITY SYSTEM
1. Does Regulation Drive Science or Does Science Drive Regulation?
SECTION 2 PRECLINICAL SAFETY ASSESSMENT
2. Absorption, Distribution, Metabolism and Excretion, Pharmacokinetics, and Safety Pharmacology
3. Preclinical Safety Assessment : General and Genetic Toxicology
4. Pharmacogenetics
SECTION 3 FIRST-IN-HUMAN TRIALS
5. Safety Planning for First-in-Human Trials
6. Pharmacokinetic and Pharmacodynamic Considerations in Safety Evaluation
SECTION 4 SAFETY ASSESSMENT IN CLINICAL TRIALS
7. Safety Monitoring in Clinical Trials
8. Introduction to Quantitative Methods and Visual Analytics in Drug Safety Data in Clinical Trials
9. Product Aggregate Safety Assessment
10. Data Monitoring Committees
SECTION 5 SIGNAL AND RISK MANAGEMENT
11. Methods of Signal Detection and Signal Management
12. Causality Assessment
13. Examples of Adverse Drug Reactions: Drug-Induced Liver Injury, Renal, Skin, Immune-Mediated Events, and Major Adverse Cardiac Events
14. Internal Safety Advisory Groups
15. Benefit-Risk Management
SECTION 6 ROLE OF EPIDEMIOLOGY AND REALWORLD EVIDENCE
16. Role of Epidemiology and Pharmacoepidemiology in the Biopharmaceutical Industry
17. Real-World Pharmacoepidemiology Studies
SECTION 7 SPECIAL POPULATIONS AND SPECIAL TOPICS
18. Pharmacovigilance in Pregnancy
19. Pharmacovigilance in Pediatrics
20. Pharmacovigilance in the Elderly
21. Vaccine Pharmacovigilance
22. Application of Human Factors and Health Literacy in Pharmacovigilance
23. Medical Device Safety Oversight and Surveillance
SECTION 8 THE NEXT FRONTIER
24. Information Technology in Pharmacovigilance: Current State and Future Directions
25. The Future of Pharmacovigilance
1. Does Regulation Drive Science or Does Science Drive Regulation?
SECTION 2 PRECLINICAL SAFETY ASSESSMENT
2. Absorption, Distribution, Metabolism and Excretion, Pharmacokinetics, and Safety Pharmacology
3. Preclinical Safety Assessment : General and Genetic Toxicology
4. Pharmacogenetics
SECTION 3 FIRST-IN-HUMAN TRIALS
5. Safety Planning for First-in-Human Trials
6. Pharmacokinetic and Pharmacodynamic Considerations in Safety Evaluation
SECTION 4 SAFETY ASSESSMENT IN CLINICAL TRIALS
7. Safety Monitoring in Clinical Trials
8. Introduction to Quantitative Methods and Visual Analytics in Drug Safety Data in Clinical Trials
9. Product Aggregate Safety Assessment
10. Data Monitoring Committees
SECTION 5 SIGNAL AND RISK MANAGEMENT
11. Methods of Signal Detection and Signal Management
12. Causality Assessment
13. Examples of Adverse Drug Reactions: Drug-Induced Liver Injury, Renal, Skin, Immune-Mediated Events, and Major Adverse Cardiac Events
14. Internal Safety Advisory Groups
15. Benefit-Risk Management
SECTION 6 ROLE OF EPIDEMIOLOGY AND REALWORLD EVIDENCE
16. Role of Epidemiology and Pharmacoepidemiology in the Biopharmaceutical Industry
17. Real-World Pharmacoepidemiology Studies
SECTION 7 SPECIAL POPULATIONS AND SPECIAL TOPICS
18. Pharmacovigilance in Pregnancy
19. Pharmacovigilance in Pediatrics
20. Pharmacovigilance in the Elderly
21. Vaccine Pharmacovigilance
22. Application of Human Factors and Health Literacy in Pharmacovigilance
23. Medical Device Safety Oversight and Surveillance
SECTION 8 THE NEXT FRONTIER
24. Information Technology in Pharmacovigilance: Current State and Future Directions
25. The Future of Pharmacovigilance